DIAGNOSIS
SIGNS AND SYMPTOMS
Classic description:
- Acute, unilateral, painless vision loss
- “Blood and thunder” appearance on fundoscopy
History
- Painless, unilateral vision loss
- If nonischemic, may be incomplete and intermittent vision loss
Physical-Exam
- Decreased visual acuity:
- Usually worse than 20/200
- Afferent pupillary defect
- Dilated tortuous veins
- Retinal hemorrhages:
- If central, findings in all 4 quadrants
- Extensive hemorrhages give a dramatic look to fundus classically described as “blood and thunder appearance.”
- Disk edema
- Cotton wool spots
ESSENTIAL WORKUP
- BP
- Visual acuity:
- Hand movements typically is all that is seen.
- Visual fields
- Fundoscopy
- Tonometry:
- Normal pressures are between 10 and 21 mm Hg.
DIAGNOSIS TESTS & NTERPRETATION
Lab
- CBC
- PT/PTT
- ESR
- ANA
- Serum protein electrophoresis
Imaging
Fluorescein angiography:
- Ophthalmologists use this to map areas of nonperfusion.
- Differentiates between ischemic and nonischemic
Diagnostic Procedures/Surgery
Gonioscopy:
- Measure iris or angle neovascularization.
DIFFERENTIAL DIAGNOSIS
- Amaurosis fugax/transient ischemic attack
- Cavernous sinus thrombosis
- DM
- HTN/hypertensive retinopathy
- Hyperviscosity syndromes:
- Sickle cell, polycythemia, leukemia, multiple myeloma
- Hysterical blindness
- Ocular ischemia syndrome
- Papilledema
- Retinal artery occlusion
- Retinal detachment
- Severe anemia with thrombocytopenia
- Temporal arteritis
- Vitreal hemorrhage
TREATMENT
PRE HOSPITAL
No specific interventions need occur prior to arrival at the hospital in regard to the eye.
INITIAL STABILIZATION/THERAPY
- Initiate steps to lower intraocular pressure (IOP) if it is elevated.
- Treat underlying medical problems.
ED TREATMENT/PROCEDURES
- Recognition and prompt ophthalmologic referral is the cornerstone of ED treatment.
- Though not proven, the following may be tried in consultation with an ophthalmologist:
- Aspirin
- Anti-inflammatory agents
- Systemic steroids
- Systemic anticoagulation
- Fibrinolytics (controversial)
- Laser chorioretinal anastomosis
MEDICATION
There is no proven treatment for CRVO, ophthalmologists may treat with the following:
- Intravitreal triamcinolone
- Antivascular endothelial growth factor:
Considerations in Prescribing
Use of oral contraceptives can increase the risk of CRVO.
FOLLOW-UP
DISPOSITION
Admission Criteria
Patients may be admitted for surgical intervention, depending upon the ophthalmologist.
Discharge Criteria
Patients can be discharged from the ED as long as they have immediate follow-up with an ophthalmologist.
Issues for Referral
- If no ophthalmologist is available, treatment should be initiated for concomitant conditions and patient transferred to nearest hospital with ophthalmologic consultation.
- Ophthalmologists often perform panretinal photocoagulation if neovascularization is found.
FOLLOW-UP RECOMMENDATIONS
- Patients with ischemic CRVO need prolonged follow-up to catch neovascularization and glaucoma that typically develop.
- Patients with CRVO likely have other vascular diseases and need complete medical workups.
- Patients should also follow with an internist to manage comorbidities and risk factors.
PEARLS AND PITFALLS
- Increased IOP resulting from neovascularization and edema can cause vascular insufficiency and with delayed treatment vision loss can be permanent.
- When patients present with bilateral CRVOs or CRVO at a young age, workup must search for hyperviscosity syndromes.
ADDITIONAL READING
- Beran DI, Murphy-Lavoie H. Acute painless vision loss.
J La State Med Soc
. 2009;161(4):214–223.
- Di Capua M, Coppola A, Albisinni R, et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion.
J Thromb Thrombolysis
. 2009.
- Khare GD, Symons RC, Do DV, et al. Common ophthalmologic emergencies.
Int J Clin Pract
. 2008;62(11):1776–1784.
- Marx JA, Hockberger RS, Walls RM, eds.
Rosen’s Emergency Medicine: Concepts and Clinical Practice
. 7th ed. St. Louis, MO: Mosby; 2010.
- McAllister IL. Central retinal vein occlusion: A review.
Clin Experiment Ophthalmol.
2012;40(1):48–58.
- Turello M, Pasca S, Daminato R, et al. Retinal vein occlusion: Evaluation of “classic” and “emerging” risk factors and treatment.
J Thromb Thrombolysis
. 2009.
- Yanoff M, Duker J.
Ophthalmology
. 3rd ed. St. Louis, MO: Mosby; 2008.
See Also (Topic, Algorithm, Electronic Media Element)
- Central Retinal Artery Occlusion
- Visual Loss
CODES
ICD9
362.35 Central retinal vein occlusion
ICD10
- H34.811 Central retinal vein occlusion, right eye
- H34.812 Central retinal vein occlusion, left eye
- H34.819 Central retinal vein occlusion, unspecified eye
CEREBRAL ANEURYSM
Veronique Au
•
Rebecca Smith-Coggins
BASICS
DESCRIPTION
- Abnormal, localized dilation or outpouching of cerebral artery wall:
- Occurs in 5–10% of population
- Rupture of saccular aneurysms account for 5–15% of strokes
- Of those that rupture:
- 40% occur at anterior communicating artery (ACA)
- 30% at internal carotid (IC)
- 20% in middle cerebral artery (MCA)
- 5–10% in vertebrobasilar artery (VBA) system
ETIOLOGY
- Asymptomatic in 3.2% of population
- “Congenital,” saccular, or berry aneurysms most common (90%):
- Develop at weak points in arterial wall and bifurcations of major cerebral arteries
- Incidence increases with age
- Multiple in 20–30%
- Increased incidence:
- Polycystic kidney disease
- Cerebral arteriovenous malformation
- Type III collagen deficiency
- Fibromuscular dysplasia
- Ehlers–Danlos syndrome
- Marfan syndrome
- Pseudoxanthoma elasticum
- Neurofibromatosis
- Moyamoya syndrome
- Coarctation of the aorta
- Tuberous sclerosis
- Sickle cell disease
- Osler–Weber–Rendu syndrome
- α1-Antitrypsin deficiency
- Systemic lupus erythematosus
- Glucocorticoid remediable hyperaldosteronism
- Arteriosclerotic, fusiform, or dolichoectatic (7%):
- More common in peripheral arteries
- Inflammatory (mycotic):
- 10% of patients with bacterial endocarditis
- Traumatic, associated with severe closed head injury
- Neoplastic, embolized tumor fragments
- Familial correlation: 1st-degree relative with history of aneurysm essentially doubles lifetime risk